Trials / Completed
CompletedNCT04342325
The Clinical Trial of ADR-001 for IgA Nephropathy
Open-label, Multiple-center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 for the Treatment for Immunoglobulin A (IgA) Nephropathy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Nagoya University · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and the tolerability of ADR-001 in Immunoglobulin A (IgA) Nephropathy patients. In addition, the investigators will evaluate the efficacy of ADR-001 for IgA Nephropathy patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | infusion of ADR-001 (Mesenchymal stem cell) | Once or twice with two week interval at a dose of 100 x 10 \^ 6 cells. |
Timeline
- Start date
- 2020-06-15
- Primary completion
- 2022-11-01
- Completion
- 2023-03-31
- First posted
- 2020-04-13
- Last updated
- 2023-05-01
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04342325. Inclusion in this directory is not an endorsement.